Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Koletex is a brand of therapeutic medical dressings and wipes developed by the Russian company Immunolex. These products utilize a biopolymer carrier, typically sodium alginate, to provide controlled and sustained release of medicinal substances directly to wounds, burns, or radiation-induced skin lesions. The product line includes several specialized formulations tailored for specific clinical needs: **Koletex-D** contains the immunomodulator sodium deoxyribonucleate (Derinat) to stimulate healing and tissue repair; **Koletex-M** incorporates the antioxidant mexidol; and **Koletex-ADL** combines the antiseptic dioxidine with local anesthetics such as lidocaine and benzocaine. Koletex dressings are primarily indicated for the prevention and treatment of radiation-induced skin reactions (radiation dermatitis) in oncology patients, as well as for the management of surgical wounds, burns, and chronic ulcers. They are designed to maintain a moist wound environment while delivering active pharmacological agents locally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Koletex.